We chat with the Founder of The Third Wave on accessibility & affordability in psychedelic medicine.
Similar Posts
Spotlight on Cannara Biotech with Nicholas Sosiak
In this episode, David Flores sits down with Cannara CFO Nicholas Sosiak, to discuss the Company’s future goals and to spotlight what differentiates Cannara from other companies in the cannabis space.
My NEW Top 5 Psychedelic Stocks for 2021 || MindMed, NUMI, Atai and More
Here are our Top 5 Best Psychedelic Stock Picks for 2021. For those who have watched our top 5 shroom stocks for 2020, you might notice that some stocks have stayed and others have been replaced because they have proven to be worthy of The Psychedelic Investor’s list by filling in the top 3 factors that we look at before investing in the psychedelic medicines industry, such as:
Clinical Trial Progress
Molecules & Compounds Pipeline
The Company’s war chest to sustain growth as a biotech company in a new industry
But why invest in psychedelic stocks?
Ever since last year, celebrity investors such as Kevin O’Leary and Peter Thiel decided to invest in the psychedelic/ shroom stocks industry, the industry grew from 2 or 3 companies to approximately 30 in 2021. This is probably one of the main reasons why we call this phenomenon the SHROOM BOOM!
But why do such investors seem to believe so much in the potential explosive growth of psychedelic stocks?
1. Psychedelics have been shown in many recent clinical trials to help a variety of mental health issues, from addiction, to depression to PTSD and more.
2.These psychedelic companies are attempting to disrupt the 100 billion annual industry for mental health pharmaceuticals.
3.These psychedelic compounds have the potential to help millions world wide, this also presents an amazing opportunity for early investors.
4.Smart investors might realize that rather than going all in on one company in the field, it is probably best to diversify your risk and create a Psychedelic Medicines portfolio.
So our top 5 Shroom Stock Pics for 2021 are:
5. Cybin ( CYBN on NEO & CLXPF on the OTC)
4. Numinus Wellness (LKYSF on the OTC & NUMI on the TSX)
3. Compass Pathways (CMPS on Nasdaq)
2. Atai Life Sciences – Soon to IPO on the Nasdaq
1 Mind Medicine or MindMed (MMED on NEO MNMD on Nasdaq & MMQ on FRA)
Link to Cybin (CYBN) : https://www.cybin.com/
Link to Numinus (NUMI) : https://numinus.ca/
Link to Compass Pathways (CMPS) : https://ir.compasspathways.com/static-files/fe6cc477-a2ee-4b4a-bd46-8f8df0b62f30
Link To Atai life Sciences: https://www.atai.life/
Linke To MindMed (MMED / MNMD / MMQ) https://mindmed.co/
Timestamps:
0:00 – Intro
1:58 – Ranking criteria
3:42 – Cybin (CYBN) ( CLXPF)
6:24 – Numinus Wellness ( NUMI)
10:04 – Compass Pathways (CMPS)
13:52 – Atai Life Sciences
18:50 – MindMed ( MMED / MNMD/ MMQ )
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Clinical trials :
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #CMPSStock
Interview With David Dardashti, Founder of Ibogaine clinic
David Dardashti talks about his Ibogaine clinic in Mexico, where he’s treated more than 8,500 people from trauma, addiction, and health issues.
Amanita Muscaria and Desert Herbalism with Ash Ritter
We dive into the world of the infamous Amanita Muscaria mushroom and learn about the wild desert apothecary of fungi and herbs.
Real Estate and Psychedelic-Assisted Therapy with Ty Zakovich, Daniel Carcillo, and Cody Shandraw
In this episode David Flores, CEO of Spotlight Media Corp, sits down with the founding members of the newly formed Healing REIT that will focus on investing in real estate designed for innovative medicine such as psychedelic-assisted therapy.
MindMed Facing Competition From HAVN? Plus Financials and Phase 2 Trials (MNMD, CYBIN, HAVN, MYCO)
Hey guys! In this week’s industry specific news, we’ll cover some interesting developments for MindMed, Mydecine, Cybin, HAVN, and a private company called WAKE. One of the biggest highlights is that HAVN might enter in direct competition with MindMed by penetrating the cluster headaches market. Stay tuned till the end the hear more on this specific news!
Timestamps:
0:00 – Intro
1:00 – MindMed Begins a Mescaline Study
4:35 – MindMed & The Chopra Foundation
8:30 – Cybin Progresses Phase 2a psilocybin study
11:56 – Mydecine announces Q1 Financials
14:16 – Havn Life Sciences enters the Cluster Headaches Game
16:30 – Wake Receives First-Ever Approval for Psilocybin for Anxiety & Depression
Enjoy!
Links:
MindMed (MNMD/ MMED / MMQ)) Begins a Mescaline Study:
https://mindmed.co/news/press-release/mindmed-announces-the-approval-of-mescaline-study/
MindMed Partners Up with The Chopra foundation:
https://mindmed.co/news/press-release/the-chopra-foundation-and-mindmed-enter-into-letter-of-intent-to-partner-on-the-future-of-psychedelic-medicines-mental-wellbeing/
Cybin (CYBN) Progresses Phase IIa psilocybin film strip study:
https://www.clinicaltrialsarena.com/news/cybin-phase-ii-psilocybin/
Mydecine (MYCO / MYCOF) Q1 Financials:
https://psilocybinalpha.com/news/mydecine-reports-first-quarter-2021-financial-results-and-provides-business-update
Havn Life Sciences (HAVN/ HAVLF/ 5NP) Begins to Study Cluster Headaches
https://havnlife.com/havn-life-enters-into-agreement-to-acquire-clinical-stage-ip-for-development-of-lsd-derived-api-for-cluster-headaches/
Wake Receives First-Ever Approval for Psilocybin Microdose Study for Anxiety and Depression
https://psychedelicspotlight.com/wake-psilocybin-microdose-study/
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #HAVN